PharmaShots | Incisive News in 3 Shots

Subscribe Now

RET-driven

Eli Lilly's Selpercatinib (LOXO-292) Receives Priority Review Status for the Treatment of RET-Driven Cancer Indications

Eli Lilly's Selpercatinib (LOXO-292) Receives Priority Review Status for the Treatment of RET-Driven Cancer Indications

January 29, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us